Cash, cash equivalents, and short-term investments of $113.1 million as of December 31, 2024, extend operational runway into the first quarter of 2026. Completion of enrollment in the ENERGY 3 pivotal ...
Caribou Biosciences, Inc. announced a strategic shift focusing on its lead oncology programs, CB-010 and CB-011, involving workforce and cost reductions aimed at extending its cash runway into the ...
Restructuring pipeline to focus on AAV cardiovascular platform (Danon disease, PKP2-ACM, BAG3-DCM) and regulatory activities for KRESLADI™ (severe LAD-I), setting foundation for near- and long-term ...
BERKELEY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced a strategic ...
Streamlining operations with cash runway expected to extend into 2Q 2026 SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a ...
- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction ...
Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to ...
BERKELEY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced a strategic ...
WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results